Lu Si Selected Research

Lu Si Research Topics

Disease

93	Melanoma (Melanoma, Malignant) 06/2024 - 08/2008
30	Neoplasms (Cancer) 05/2024 - 05/2014
13	Neoplasm Metastasis (Metastasis) 01/2024 - 08/2008
13	Disease Progression 01/2023 - 07/2011
10	Renal Cell Carcinoma (Grawitz Tumor) 01/2022 - 11/2012
4	Breast Neoplasms (Breast Cancer) 01/2021 - 07/2014
3	Diarrhea 01/2023 - 05/2018
3	Carcinoma (Carcinomatosis) 01/2023 - 05/2016
3	Lymphatic Metastasis 01/2021 - 12/2013
2	Vomiting 01/2023 - 11/2012
2	Proteinuria 01/2023 - 05/2020
2	Leukopenia 01/2023 - 05/2020
2	Dermatitis 01/2023 - 05/2018
2	Pneumonia (Pneumonitis) 12/2022 - 01/2022
2	Thrombocytopenia (Thrombopenia) 05/2020 - 10/2014
1	Sarcoma (Soft Tissue Sarcoma) 06/2024
1	Extramammary Paget Disease (Paget Disease, Extramammary) 05/2024
1	Paronychia 01/2023
1	Exanthema (Rash) 01/2023
1	Chemical and Drug Induced Liver Injury 01/2023
1	Edema (Dropsy) 01/2023
1	Asthenia 01/2023
1	Liver Cirrhosis (Hepatic Cirrhosis) 03/2022
1	Anemia 01/2022

Drug/Important Bio-Agent (IBA)

8	Immune Checkpoint InhibitorsIBA 01/2023 - 01/2021
7	InterferonsIBA 02/2023 - 07/2011
7	Biomarkers (Surrogate Marker)IBA 01/2023 - 10/2017
6	Monoclonal AntibodiesIBA 02/2023 - 12/2014
6	Temozolomide (Temodar)FDA LinkGeneric 01/2023 - 08/2013
5	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 03/2024 - 01/2018
5	pembrolizumabIBA 01/2024 - 04/2017
5	Everolimus FDA Link 05/2020 - 02/2012
5	Imatinib Mesylate (Gleevec)FDA Link 03/2019 - 07/2011
4	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 06/2024 - 08/2018
4	dabrafenibIBA 05/2024 - 01/2020
4	trametinibIBA 05/2024 - 01/2020
4	apatinibIBA 01/2023 - 10/2018
4	camrelizumabIBA 01/2023 - 01/2020
4	Phosphotransferases (Kinase)IBA 11/2022 - 01/2012
4	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 10/2021 - 05/2014
4	palbociclibIBA 01/2021 - 11/2017
4	Sorafenib (BAY 43-9006)FDA Link 01/2018 - 11/2012
4	Tyrosine Kinase InhibitorsIBA 09/2014 - 07/2011
3	phosphatidyl-N-monomethylaminoethanolIBA 05/2024 - 01/2019
3	Programmed Cell Death 1 ReceptorIBA 08/2023 - 01/2020
3	Messenger RNA (mRNA)IBA 01/2022 - 12/2021
3	RNA (Ribonucleic Acid)IBA 01/2022 - 11/2019
3	Axitinib (AG 013736)IBA 01/2022 - 11/2019
3	Arsenic Trioxide (Trisenox)FDA Link 01/2019 - 06/2014
3	Cisplatin (Platino)FDA LinkGeneric 01/2018 - 11/2012
3	DNA (Deoxyribonucleic Acid)IBA 11/2017 - 01/2012
3	Sunitinib (Sutent)FDA Link 05/2016 - 10/2014
3	glabridinIBA 05/2016 - 01/2014
2	Immunoconjugates (Immunoconjugate)IBA 05/2024 - 01/2021
2	Epidermal Growth Factor (EGF)IBA 01/2024 - 01/2019
2	Immunoglobulins (Immunoglobulin)IBA 02/2023 - 11/2019
2	LigandsIBA 01/2023 - 09/2014
2	Bevacizumab (Avastin)FDA Link 11/2022 - 10/2021
2	AntibodiesIBA 10/2022 - 05/2022
2	Immunoglobulin G (IgG)IBA 05/2022 - 01/2022
2	toripalimabIBA 01/2022 - 11/2019
2	IpilimumabIBA 01/2022 - 04/2017
2	Adenylyl Cyclases (Adenylyl Cyclase)IBA 01/2022 - 01/2019
2	Paclitaxel (Taxol)FDA LinkGeneric 10/2021 - 05/2019
2	B7-H1 AntigenIBA 01/2021 - 11/2019
2	Cyclin-Dependent Kinase 4IBA 01/2021 - 12/2018
2	MicroRNAs (MicroRNA)IBA 05/2019 - 01/2019
2	Telomerase (Telomerase Reverse Transcriptase)IBA 01/2018 - 10/2017
2	MTOR InhibitorsIBA 01/2018 - 01/2017
2	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 01/2018 - 09/2017
2	Mitogen-Activated Protein KinasesIBA 09/2014 - 09/2014
2	Dacarbazine (DIC)FDA LinkGeneric 07/2013 - 08/2008
1	disitamab vedotinIBA 05/2024
1	hydrogen sulfite (bisulfite)IBA 05/2024
1	ErbB Receptors (EGF Receptor)IBA 01/2024
1	Extracellular Matrix ProteinsIBA 12/2023
1	Matrix Metalloproteinases (MMPs)IBA 12/2023
1	anlotinibIBA 08/2023
1	Transaminases (Aminotransferases)IBA 01/2023
1	Creatine Kinase (Creatine Phosphokinase)IBA 01/2023
1	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 01/2023
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2023
1	Alanine Transaminase (SGPT)IBA 01/2023
1	Myosin Type IIIBA 11/2022
1	atezolizumabIBA 11/2022
1	larotrectinibIBA 11/2022
1	tyrosine receptor (receptor, tyrosine)IBA 11/2022
1	entrectinibIBA 11/2022
1	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2022
1	NivolumabIBA 01/2022

Therapy/Procedure

53	Therapeutics 06/2024 - 03/2013
23	Immunotherapy 03/2024 - 09/2014
11	Drug Therapy (Chemotherapy) 02/2023 - 08/2008
2	Adjuvant Radiotherapy 06/2024 - 03/2024
2	Molecular Targeted Therapy 11/2023 - 03/2013
2	Oncolytic Virotherapy 01/2022 - 01/2020
2	Injections 01/2022 - 01/2018
1	Radiotherapy 03/2024
1	Lenses 03/2022
1	Adjuvant Chemotherapy 01/2022